Darunavir/cobicistat
Darunavir/cobicistat (trade name Prezcobix) is an antiretroviral medication used to treat and prevent HIV/AIDS. It is a fixed dose combination drug containing 800 mg of darunavir and 150 mg of cobicistat.[1] Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.
| Combination of | |
|---|---|
| Darunavir | HIV protease inhibitor |
| Cobicistat | Cytochrome P450 (CYP3A) inhibitor |
| Clinical data | |
| Trade names | Prezcobix |
| Identifiers | |
| KEGG | |
It was approved by the Food and Drug Administration for use in United States in 2015.[2]
References
- "Darunavir / Cobicistat". AIDSinfo. U.S. Department of Health and Human Services.
- "Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA". Medscape. January 30, 2015.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.